For Bayer, one of the world's leading specialty pharmaceutical companies, patients' health always comes first. Exchanging ideas and information with patient organizations on the basis of mutual trust is an important component of our work.
The patient comes first
Such cooperation helps us to understand the needs of patients as they come to terms with their illness. This enables us to gear our research and development to these needs and to continue working on improved, new drugs and therapies.
Bayer cooperates with patient organizations in all kinds of therapeutic areas. We attach great importance to transparency in this context and protect the independence of our cooperation partners.
Cooperation between Bayer and patient organizations is based on the following principles.
- In order to provide patients with quality medical healthcare, a partnership with a patient organization pursues a specific objective concentrating on one or more of the following areas:
- raising awareness for certain diseases by improving diagnostic possibilities and preventive measures, knowing the patients' prospects and needs,
- understanding diseases and making sure that patients receive the best medical treatment available,
- improving the information provided to the patients,
- supporting medical innovations.
- Bayer and the patient organizations comply with international and national laws and regulations.
- Cooperation with a patient organization should neither influence decisions on a therapy nor promote or support specific therapies.
- Bayer respects the neutrality and independence of patient organizations. Cooperation is based on a partnership between equals in which transparency and clarity are fundamental principles. This is why we also provide information on the extent and nature of support.
Overview of cooperation with patient organizations in Europe in 2018
The following is a list of patient organizations with which Bayer and its affiliated companies in Europe cooperated in 2018.
|Patient Organizations||Country of Organization's Office||Nature and Purpose of Support||Value in Local Currency||Value in Euro||Travel costs in EURO|
|International Diabetes Federation (IDF)||Belgium||Contribution to IDF's efforts to improve the life of people living with diabetes||30,000.00||no|
|Asociacion de Hemofilia de la Communidad Valencia||Spain||Support activities of PO regarding their educational activity "Cycling for Hemophilia 2018"||40,000.00||no|
|IAPB (International Agency for the Prevention of Blindness)||UK||Support of patron level membership||100,000.00 USD||88,398.70||no|
|International Agency for the Prevention of Blindness (IAPB)||UK||Support of PO regarding their World Sight Day Photo Competition 2018, October 11, 2018||30,000.00 USD||26,519.60||no|
|European Pulmonary Hypertension Association (PHA Europe)||Austria||Support of PO regarding the distribution of educational materials for patients on a novel nebulizing device "Breelib"||50,000.00||no|
|Federation of European Scleroderma Associations (FESCA)||Belgium||Support of PO in organizing their World Scleroderma Day (WSD) in 2018 and Campaign Conceptualization||25,000.00||no|
|European Pulmonary Hypertension Association (PHA Europe)||Austria||Support of PO's activities in 2018||100,000.00||no|
|EURORDIS (European Rare Diseases Organisation)||France||One-year membership of the PO’s "Round Table of Companies"||5,000.00||no|
|Stroke Alliance for Europe (SAFE)||UK||Support of PO in organizing the SAFE Working Conference and General Assembly November 27-30, 2018, Berlin, Germany||90,000.00||no|
|European Pulmonary Hypertension Association (PHA Europe)||Austria||PO's representatives provide consultancy and advisory service on production of patient videos regarding Patient Advocacy/Pulmonary Hypertension||7,800.00||644.00|
|Stroke Alliance for Europe (SAFE)||UK||Support of PO in organizing the "Stroke Education and Training Programme" in 2018||334,056.00||no|
|EHC (European Haemophlilia Consortium)||Belgium||One-year membership of the PO’s Corporate Giving Program. One-year membership of the EHCs Round Tables.||45,000.00||no|
|EHC (European Haemophlilia Consortium)||Belgium||Support of PO regarding their Annual Conference, October 5-7, 2018, Brussel, Belgium||37,000.00||no|
|Baltic States||Reports can be received from||UAB Bayer Baltic Republics (Estonia, Latvia, Lithuania)
Alina Tikuišiene MD
Zirmunu str. 68A
|Belgium/Luxemburg (French)||Country website|
|Belgium/Luxemburg (Dutch)||Country website|
|Czech Republic||Country website|
|Estonia||Reports can be received from||UAB Bayer Baltic Republics (Estonia, Latvia, Lithuania)
Alina Tikuišiene MD
Zirmunu str. 68A
|Iceland||Reports can be received from||Bayer AB- Bayer Scandinavia
Gustav III:s Boulevard 56
169 26 Solna
|Romania||Reports can be received from||SC Bayer SRL
Bayer Pharmaceuticals Division
Sos. Pipera nr. 42., Sector 2
NUSCO Tower fl. 1,16,17
|Serbia||Reports can be received from||Bayer Pharma d.o.o.
Omladinskih brigada 88b
|Slovenia||Reports can be received from||Bayer d.o.o.
Lucija Zlodi Gosnik